Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules; and GeneStrat tumor profiling and VeriStrat immune profiling tests that provide physicians with timely results to facilitate treatment decisions. It also provides Bio-Rad SARS-CoV-2 ddPCR test, which is designed to detect the presence of infection by the SARS-CoV-2 virus; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. In addition, the company offers include diagnostic research, clinical research, development, and testing services to biopharmaceutical companies, as well as discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
IPO Year: 2020
Exchange: NASDAQ
Website: biodesix.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/16/2024 | Sector Outperform | Scotiabank | |
| 7/26/2024 | $3.00 | Buy | Craig Hallum |
| 5/13/2024 | $2.80 | Buy | TD Cowen |
| 5/3/2024 | $3.00 | Buy | Lake Street |
| 11/17/2021 | $21.00 → $11.00 | Overweight → Equal-Weight | Morgan Stanley |
EFFECT - BIODESIX INC (0001439725) (Filer)
EFFECT - BIODESIX INC (0001439725) (Filer)
424B3 - BIODESIX INC (0001439725) (Filer)
424B5 - BIODESIX INC (0001439725) (Filer)
S-3 - BIODESIX INC (0001439725) (Filer)
S-3 - BIODESIX INC (0001439725) (Filer)
10-Q - BIODESIX INC (0001439725) (Filer)
8-K - BIODESIX INC (0001439725) (Filer)
8-K - BIODESIX INC (0001439725) (Filer)
424B5 - BIODESIX INC (0001439725) (Filer)
4 - BIODESIX INC (0001439725) (Issuer)
4 - BIODESIX INC (0001439725) (Issuer)
4 - BIODESIX INC (0001439725) (Issuer)
4 - BIODESIX INC (0001439725) (Issuer)
4 - BIODESIX INC (0001439725) (Issuer)
4 - BIODESIX INC (0001439725) (Issuer)
4 - BIODESIX INC (0001439725) (Issuer)
4 - BIODESIX INC (0001439725) (Issuer)
4 - BIODESIX INC (0001439725) (Issuer)
4 - BIODESIX INC (0001439725) (Issuer)
Biodesix, Inc. (NASDAQ:BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the appointment of Lawrence (Lair) T. Kennedy, Jr. to the Company's Board of Directors (Board) and Audit Committee of the Board effective January 3, 2023. Mr. Kennedy brings to Biodesix more than 20 years of broad operating, corporate finance, company creation and investment experience with a specific focus in the healthcare industry. "We are delighted to welcome Lair to Biodesix's Board of Directors," said Scott Hutton, Chief Executive Officer of Biodesix. "He brings a wealth of business experience with a strong background in healthcare and diagnostics. We look fo
Biodesix, Inc. (NASDAQ:BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced the appointment of Dr. Jon Faiz Kayyem to the company's board of directors. Dr. Kayyem's diverse career spans more than 20 years and includes experience in academia, lean startups, and Fortune 100 companies. He has served in various leadership positions throughout his career including numerous roles at GenMark Diagnostics, including Founder, CEO and President, Chief Scientific Officer, Senior Vice President of Research and Development. Prior to his work at GenMark Diagnostics, Dr. Kayyem served as Director and Founder of Calimmune and was Vice President of Life Sciences a
Q3 2024 revenue grew 35% over Q3 2023 to $18.2 million; Q3 2024 gross profit margin of 77.0%, up from 76.1% in Q3 2023; Q3 2024 Net loss improved by 6% compared to Q3 2023; Conference Call and Webcast Today at 8:30 a.m. ET LOUISVILLE, Colo., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the third quarter ended September 30, 2024. "The Biodesix team is pleased to report another solid quarter focused on executing and delivering on our three main goals - driving revenue growth through the adoption of our lung diagnostic tests and biopharma services, continued implementation
LOUISVILLE, Colo., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will participate in three upcoming investor conferences: Craig-Hallum 15th Annual Alpha Select Conference1x1 MeetingsDate: Tuesday, November 19, 2024Location: New York, NY Wolfe Research Healthcare Conference 20241x1 MeetingsDate: Wednesday, November 20, 2024Location: New York, NY Canaccord Genuity Medtech, Diagnostics and Digital Health & Services Forum Presentation and 1x1 MeetingsPresentation Date and Time: Thursday, November 21, 2024 at 1
Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the third quarter ended September 30, 2024 before the start of trading on Friday, November 1. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 8:30 a.m. Eastern Time on the same day. Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion
Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that members of the Biodesix management team will present at two upcoming investor conferences: Lake Street Capital Markets 8th Annual Best Ideas Growth Conference Date: Thursday, September 12, 2024 Location: The Yale Club, New York, NY Presenter: Scott Hutton, CEO of Biodesix Colorado BioScience Association (CBSA) Rocky Mountain Life Sciences Investor and Partnering Conference Dates: September 12-13, 2024 Location: Beaver Run Resort & Conference Center, Breckenridge, CO Presenter: Robin Cowie, CFO of Biodesix About Biodesix Biodesix is a leading diagnostic solutions co
Q2 2024 revenue grew 51% over Q2 2023 to $17.9 million; Q2 2024 gross profit margin of 78.4%, a 5.7% improvement from Q2 2023; Raises full-year 2024 revenue guidance to $70-72 million from $65-68 million; Q2 24 Net loss, including certain non-cash items, and Adjusted EBITDA improved by 19% and 38% over Q2 2023; Conference Call and Webcast Today at 4:30 p.m. ET Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the second quarter ended June 30, 2024. "The second quarter marks sustained excellence in our execution, resulting in outstanding revenue growth coupled with consistently strong gross margins, and c
Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton, Chief Executive Officer of Biodesix, will present in a fireside chat and host in-person 1x1 investor meetings at Canaccord Genuity's 44th Annual Growth Conference, which will be held from August 13-14, 2024. Canaccord Genuity's 44th Annual Growth Conference Fireside Chat Date: Wednesday, August 14, 2024 Fireside Chat Time: 1:00 PM ET Location: InterContinental Boston, Boston, MA The presentation will be webcast live and available for replay under "News & Events" in the Investors section of Biodesix's website at Biodesix.com. About Biodesix Biodesix is
Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, announced today that it will release financial results for the second quarter ended June 30, 2024 after the close of trading on Wednesday, August 7. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Participants are advised to jo
Awarding Excellence in Company Culture Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, is honored to announce it has been named to Inc. Magazine's Best Workplaces list. The ranking is a result of a comprehensive, data-driven measurement process to identify which American companies have excelled in creating exceptional workplaces with great company cultures. After collecting data from thousands of submissions, Inc. selected 543 honorees this year. Each company that was nominated took part in a comprehensive employee survey, conducted by Quantum Workplace, which included topics such as management effectiveness, perks, recognition, fostering employee growth, and overa
Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, will participate in two upcoming investor conferences: William Blair 44th Annual Growth Stock Conference Presentation and 1x1 Meetings Presentation Date and Time: Tuesday, June 4, 2024 at 10:40 AM CT Location: Chicago, IL Jefferies Global Healthcare Conference Presentation and 1x1 Meetings Presentation Date and Time: Thursday, June 6, 2024 at 8:30 AM ET Location: New York, NY The presentations will be webcast live and available for replay under "News & Events" in the Investors section of the Company's website at www.biodesix.com. A
Data highlights ability of the Nodify XL2 test to identify benign nodules in patients with emphysema Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company with a focus in lung disease, announced that new data will be presented today at the 2024 American Thoracic Society (ATS) International Conference in San Diego, California. The presentation, titled "Performance comparison of a blood-based integrated classifier for lung nodule risk stratification in patients with versus without emphysema," will be presented by Arthur Romero MD, MSC, FCCP, Associate Professor of Pulmonary and Critical Care Medicine at the University of Nevada Las Vegas. Emphysema is a common comorbid pulm
SC 13G/A - BIODESIX INC (0001439725) (Subject)
SC 13G - BIODESIX INC (0001439725) (Subject)
SC 13D/A - BIODESIX INC (0001439725) (Subject)
SC 13D/A - BIODESIX INC (0001439725) (Subject)
SC 13G - BIODESIX INC (0001439725) (Subject)
SC 13D/A - BIODESIX INC (0001439725) (Subject)
SC 13D/A - BIODESIX INC (0001439725) (Subject)
SC 13D/A - BIODESIX INC (0001439725) (Subject)
SC 13D/A - BIODESIX INC (0001439725) (Subject)
SC 13G/A - BIODESIX INC (0001439725) (Subject)
4 - BIODESIX INC (0001439725) (Issuer)
4 - BIODESIX INC (0001439725) (Issuer)
4 - BIODESIX INC (0001439725) (Issuer)
4 - BIODESIX INC (0001439725) (Issuer)
4 - BIODESIX INC (0001439725) (Issuer)
4 - BIODESIX INC (0001439725) (Issuer)
Q3 2024 revenue grew 35% over Q3 2023 to $18.2 million; Q3 2024 gross profit margin of 77.0%, up from 76.1% in Q3 2023; Q3 2024 Net loss improved by 6% compared to Q3 2023; Conference Call and Webcast Today at 8:30 a.m. ET LOUISVILLE, Colo., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the third quarter ended September 30, 2024. "The Biodesix team is pleased to report another solid quarter focused on executing and delivering on our three main goals - driving revenue growth through the adoption of our lung diagnostic tests and biopharma services, continued implementation
Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the third quarter ended September 30, 2024 before the start of trading on Friday, November 1. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 8:30 a.m. Eastern Time on the same day. Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion
Q2 2024 revenue grew 51% over Q2 2023 to $17.9 million; Q2 2024 gross profit margin of 78.4%, a 5.7% improvement from Q2 2023; Raises full-year 2024 revenue guidance to $70-72 million from $65-68 million; Q2 24 Net loss, including certain non-cash items, and Adjusted EBITDA improved by 19% and 38% over Q2 2023; Conference Call and Webcast Today at 4:30 p.m. ET Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the second quarter ended June 30, 2024. "The second quarter marks sustained excellence in our execution, resulting in outstanding revenue growth coupled with consistently strong gross margins, and c
Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, announced today that it will release financial results for the second quarter ended June 30, 2024 after the close of trading on Wednesday, August 7. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Participants are advised to jo
Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that it will release financial results for the first quarter ended March 31, 2024 after the close of trading on Wednesday, May 8. Biodesix's management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Pa
Persistent, high double-digit growth in Lung Diagnostic test volume - growing 65% in FY2023 versus FY2022 - and the sixth consecutive quarter with greater than 50% year-over-year growth; Ongoing improvement in gross profit margin with achievement of 77% in fourth quarter 2023, up 11 points over fourth quarter 2022; 2024 Total Revenue Guidance of $65 million to $68 million; Conference Call and Webcast Today at 8:30 a.m. ET Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions and services company, today provided a corporate update and announced its financial and operating results for the fourth quarter and year ended December 31, 2023 (fiscal 2023). "I am exceptionally proud
Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that it will release financial results for the fourth quarter and year ended December 31, 2023 before the open of trading on Friday, March 1. Biodesix's management will host a conference call and webcast to discuss its financial results and provide a general business update at 8:30 a.m. Eastern Time on the same day. Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's co
Third quarter 2023 Lung Diagnostic test volume grew 60% over the comparable period in 2022 and 6% over second quarter of 2023; Third quarter 2023 gross profit margin of 76% versus 67% for the third quarter 2022 and 73% for the second quarter of 2023; Net loss, which includes certain non-cash items, of $10.9 million improved by 20% over the comparable period in 2022 and 18% over the second quarter of 2023; Adjusted EBITDA of ($5.4 million) improved by 40% over both the third quarter of 2022 and the second quarter of 2023; Conference Call and Webcast Today at 4:30 p.m. ET Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company with a focus in lung disease, today announ
Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company with a focus on lung disease, announced today that it will release financial results for the third quarter ended September 30, 2023 after the close of trading on Tuesday, November 7. Biodesix's management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session should use this link. A replay of the webcast will be available via the Company's investor website approximately two hours after the call's conclus
Second quarter 2023 Core Lung Diagnostic revenue of $11.4 million increased 58% over the comparable period in 2022 and 33% over the first quarter of 2023; Second quarter 2023 gross profit margin of 73% versus 64% for the second quarter 2022 and 65% for the first quarter 2023; Revenue continues to track to 2023 full year guidance of $52-55 million; Approximately $27.5 million in common shares sold under a private placement from the Company's largest investors, Board of Directors members, and Executive Leadership team; Multiple publications and data presentations on the clinical utility and health economic benefits of Core Lung Diagnostics tests; Conference Call and Webcast Today at
Scotiabank initiated coverage of Biodesix with a rating of Sector Outperform
Craig Hallum initiated coverage of Biodesix with a rating of Buy and set a new price target of $3.00
TD Cowen initiated coverage of Biodesix with a rating of Buy and set a new price target of $2.80
Lake Street initiated coverage of Biodesix with a rating of Buy and set a new price target of $3.00
Morgan Stanley downgraded Biodesix from Overweight to Equal-Weight and set a new price target of $11.00 from $21.00 previously
Morgan Stanley reiterated coverage of Biodesix with a rating of Overweight and set a new price target of $23.00 from $25.00 previously
Morgan Stanley reiterated coverage of Biodesix with a rating of Overweight and set a new price target of $25.00 from $20.00 previously
Canaccord Genuity reiterated coverage of Biodesix with a rating of Buy and set a new price target of $31.00 from $27.00 previously
TD Cowen analyst Dan Brennan initiates coverage on Biodesix (NASDAQ:BDSX) with a Buy rating and announces Price Target of $2.8.
Biodesix (NASDAQ:BDSX) reported quarterly losses of $(0.14) per share which met the analyst consensus estimate. This is a 41.67 percent increase over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $14.818 million which beat the analyst consensus estimate of $14.180 million by 4.50 percent. This is a 63.63 percent increase over sales of $9.056 million the same period last year.
Lake Street initiates coverage on Biodesix (NASDAQ:BDSX) with a Buy rating and announces Price Target of $3.
These presentations highlight advancements in liquid biopsy technologies that detect cell free DNA (cfDNA) and the clinical value of rapid turnaround time to detect actionable tumor mutations in a real-world clinical setting.
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 200 points on Friday. The Dow traded up 0.89% to 38,941.18 while the NASDAQ rose 1.26% to 16,251.98. The S&P 500 also rose, gaining, 1.10% to 5,203.90. Check This Out: Top 3 Materials Stocks That May Explode This Quarter Leading and Lagging Sectors Communication services shares jumped by 1.8% on Friday. In trading on Friday, utilities shares rose by just 0.2%. Top Headline U.S. employers added 303,000 nonfarm payrolls in March, marking an increase from the 270,000 reading in February and surpassing the expected 212,000, the Bureau of Labor Statistics said Friday. The unemplo
Shares of Byrna Technologies Inc. (NASDAQ:BYRN) rose sharply during Friday’s session after the company reported better-than-expected first-quarter revenue, and announced a CFO transition. Byrna Technologies posted quarterly sales of $16.65 million, topping market estimates of $11.49 million, according to data from Benzinga Pro. The company also said its CFO David North will retire later this year. Byrna Technologies shares jumped 7.1% to $14.74 on Friday. Here are some other stocks moving in today's mid-day session. Gainers MediaCo Holding Inc. (NASDAQ:MDIA) shares jumped 141.7% to $3.4106 after a 13D amended filing showed Standard General L.P. reported a 95.2% stake in the company a
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Friday. The Dow traded up 1.01% to 38,987.23 while the NASDAQ rose 1.50% to 16,289.37. The S&P 500 also rose, gaining, 1.29% to 5,213.49. Check This Out: Top 3 Materials Stocks That May Explode This Quarter Leading and Lagging Sectors Communication services shares jumped by 1.9% on Friday. In trading on Friday, utilities shares rose by just 0.2%. Top Headline U.S. employers added 303,000 nonfarm payrolls in March, marking an increase from the 270,000 reading in February and surpassing the expected 212,000, the Bureau of Labor Statistics said Friday. The unemployme
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Friday. Following the market opening Friday, the Dow traded up 0.30% to 38,713.29 while the NASDAQ rose 0.35% to 16,105.67. The S&P 500 also rose, gaining, 0.35% to 5,165.43. Check This Out: Top 3 Materials Stocks That May Explode This Quarter Leading and Lagging Sectors Communication services shares jumped by 0.6% on Friday. In trading on Friday, utilities shares fell by 0.3%. Top Headline U.S. employers added 303,000 nonfarm payrolls in March, marking an increase from the 270,000 reading in February and surpassing the expected 212,000, the Bureau of Labor Statistics said Friday.